Description

Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2S,3S)-, compd. with methyl (4S)-8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetate (1:1) is a high-purity, non-racemic salt complex designed for advanced pharmaceutical research and development. This compound is critical for its role as a key synthetic intermediate or active pharmaceutical ingredient (API) precursor in the development of targeted therapeutics. It is primarily utilized by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the synthesis of complex, chiral drug molecules.

Application

• Pharmaceutical Intermediate: Serves as a critical building block in the multi-step synthesis of novel, chiral drug candidates, particularly in oncology and central nervous system (CNS) therapeutic areas.
• Active Pharmaceutical Ingredient (API) Research: Used in preclinical and clinical research for the development of new chemical entities (NCEs) targeting specific biological pathways.
• Process Chemistry & Scale-Up: Employed in process development and optimization studies for the commercial-scale manufacturing of complex pharmaceuticals.
• Reference Standard: Acts as a high-purity analytical standard for method development, validation, and quality control in pharmaceutical analysis.
• Medicinal Chemistry: Utilized in structure-activity relationship (SAR) studies to explore and optimize the biological activity of quinazoline and piperazine-based compounds.
• Contract Research & Manufacturing (CRAM): Supplied to organizations providing custom synthesis and development services for the global pharmaceutical industry.

Basic Information

Product Name	Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2S,3S)-, compd. with methyl (4S)-8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetate (1:1)
CAS No.	917389-30-1
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	Methyl (4S)-8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetate (2S,3S)-2,3-bis(4-methylbenzoyloxy)succinate (1:1); (2S,3S)-2,3-Bis(4-methylbenzoyloxy)succinic acid compound with methyl (4S)-8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetate (1:1); API Intermediate 917389-30-1; Chiral Quinazoline-Piperazine Salt Complex.
EINECS	Contact for details

Quality Control

Our products undergo rigorous quality testing to ensure compliance with industry standards. Every batch is characterized using advanced analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity, chiral purity, and chemical potency. Certificates of Analysis (COA) detailing purity, impurity profile, and other critical parameters are available upon request. Our quality management system supports development under GMP-like conditions for research use, ensuring traceability and consistency for critical pharmaceutical applications.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or as specified on the label or Certificate of Analysis. This material is typically hygroscopic (moisture-sensitive); therefore, the container must be kept tightly sealed in a dry environment. For long-term storage, consider under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Chiral Purity	≥ 99.0% de
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Water Content (KF)	≤ 1.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.